Anti‐interleukin‐17A and anti‐interleukin‐23 antibodies may be effective against Alzheimer's disease: Role of neutrophils in the pathogenesis
Open Access
- 17 December 2019
- journal article
- review article
- Published by Wiley in Brain and Behavior
- Vol. 10 (1) , e01504
Abstract
Introduction: Despite the remarkable progress achieved in the research on Alzheimer's disease (AD), its exact pathogenesis is not fully understood and effective therapies do not currently exist. In order to find effective therapy for AD, I ranged extensively over the literature and found an important paper by Tiffany and colleagues.Results and Conclusion: Neuroinflammation has been proposed as a possible cause or driving force of AD. The discovery by Tiffany et al. that amyloid β (Aβ) is a formylpeptide receptor 2 agonist indicated that Aβ is a potent chemoattractant for phagocytic leukocytes. Therefore, in all likelihood Aβ attracts peripheral blood neutrophils, monocytes, as well as microglia cells in brain parenchyma, and activates them. However, the role of microglia cells and their precursor monocytes in AD pathogenesis remains elusive. Recently, neutrophils were found to be present in areas with Aβ deposits in AD brain and in transgenic AD model mice. Because brain is vulnerable to the effects of reactive oxygen species (ROS) and neutrophils secrete a large amount of ROS, neutrophils look like a driving force of AD. Therefore, a possibility arises that anti‐IL‐17A and anti‐IL‐23 antibodies are effective against AD, because these antibodies can be thought to interfere with neutrophil trafficking from the bone marrow to the blood circulation and thus inhibit neutrophil infiltration into AD brain. Clinical studies using anti‐IL‐17A and anti‐IL‐23 antibodies in patients with AD are required.Keywords
This publication has 53 references indexed in Scilit:
- Microfluidic Chemotaxis Platform for Differentiating the Roles of Soluble and Bound Amyloid-β on Microglial AccumulationScientific Reports, 2013
- Oxidative Stress and the Pathogenesis of Alzheimer's DiseaseOxidative Medicine and Cellular Longevity, 2013
- Mechanism of Oxidative Stress in NeurodegenerationOxidative Medicine and Cellular Longevity, 2012
- Alzheimer's DiseaseNew England Journal of Medicine, 2010
- Effector mechanisms of interleukin-17 in collagen-induced arthritis in the absence of interferon-γ and counteraction by interferon-γArthritis Research & Therapy, 2009
- Formyl peptide receptors are candidate chemosensory receptors in the vomeronasal organProceedings of the National Academy of Sciences, 2009
- Neutrophil mobilization and clearance in the bone marrowImmunology, 2008
- Granulocyte colony-stimulating factor delays neutrophil apoptosis by inhibition of calpains upstream of caspase-3Blood, 2008
- Amyloid-β Induces Chemotaxis and Oxidant Stress by Acting at Formylpeptide Receptor 2, a G Protein-coupled Receptor Expressed in Phagocytes and BrainJournal of Biological Chemistry, 2001
- Activation of NADPH Oxidase in Alzheimer's Disease BrainsBiochemical and Biophysical Research Communications, 2000